These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30195702)

  • 1. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
    Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
    J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
    J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
    J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
    Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
    Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
    Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
    Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
    Liu SY; Gou LY; Li AN; Lou NN; Gao HF; Su J; Yang JJ; Zhang XC; Shao Y; Dong ZY; Zhou Q; Zhong WZ; Wu YL
    J Thorac Oncol; 2016 Sep; 11(9):1503-10. PubMed ID: 27257131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
    Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
    Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
    J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Sands JM; Nguyen T; Shivdasani P; Sacher AG; Cheng ML; Alden RS; Jänne PA; Kuo FC; Oxnard GR; Sholl LM
    Lung Cancer; 2020 Feb; 140():35-41. PubMed ID: 31855703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
    Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
    Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
    Sui JSY; Finn SP; Gray SG
    Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
    Baldacci S; Figeac M; Antoine M; Descarpentries C; Kherrouche Z; Jamme P; Copin MC; Tulasne D; Nanni I; Beau-Faller M; Melaabi S; Levallet G; Quoix E; Moro-Sibilot D; Friard S; Missy P; Barlesi F; Cadranel J; Cortot AB
    J Thorac Oncol; 2020 Jan; 15(1):120-124. PubMed ID: 31605799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
    Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
    J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.